Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
South Africa
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Bms-986165
1. Bms-986165
2. 1609392-27-9
3. Tyk2-in-4
4. Bms986165
5. Deucravacitinib [usan]
6. N0a21n6rau
7. 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-n-(trideuteriomethyl)pyridazine-3-carboxamide
8. Deucravacitinib (usan)
9. Sotyktu
10. Unii-n0a21n6rau
11. Deucravacitinib [inn]
12. Deucravacitinib [jan]
13. Chembl4435170
14. Deucravacitinib [who-dd]
15. Schembl20520348
16. Gtpl10432
17. Ex-a3154
18. Bdbm50507816
19. Mfcd31715455
20. Nsc825520
21. S8879
22. Tyk2-in-4(bms986165)
23. Who 11342
24. At18623
25. Nsc-825520
26. Compound 11 [pmid: 31318208}
27. Ncgc00687789-01
28. Ac-31543
29. Hy-117287
30. Cs-0065044
31. D11817
32. 3-pyridazinecarboxamide, 6-((cyclopropylcarbonyl)amino)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)-
33. 3-pyridazinecarboxamide, 6-((cyclopropylcarbonyl)amino]-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)n-(methyl-d3)-
34. 6-((cyclopropylcarbonyl)amino)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(2h3)methyl-3-pyridazine-carboxamide
35. 6-((cyclopropylcarbonyl)amino]-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-((2h3)methyl)pyridazine-3-carboxamide
36. 6-[(cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl]amino]-n-(methyl-d3)-3-pyridazinecarboxamide
Molecular Weight | 425.5 g/mol |
---|---|
Molecular Formula | C20H22N8O3 |
XLogP3 | 1.2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 7 |
Exact Mass | 425.20031683 g/mol |
Monoisotopic Mass | 425.20031683 g/mol |
Topological Polar Surface Area | 136 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 648 |
Isotope Atom Count | 3 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of psoriasis
Treatment of Systemic Lupus Erythematosus (SLE)
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L - Antineoplastic and immunomodulating agents
L04 - Immunosuppressants
L04A - Immunosuppressants
L04AA - Selective immunosuppressants
L04AA56 - Deucravacitinib
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41294
Submission : 2025-02-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40962
Submission : 2025-03-28
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2025-04-23
Pay. Date : 2025-04-04
DMF Number : 41626
Submission : 2025-03-28
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41638
Submission : 2025-03-31
Status : Active
Type : II
About the Company : Farmhispania Group comprises two companies in Spain: Farmhispania in Barcelona and Rolabo in Zaragoza. Since its inception, the group has consistently invested in advanced equipmen...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
About the Company : Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its produc...
About the Company : Since its founding in 1962, MOEHS has produced Active Pharmaceutical Ingredients (APIs) for the international pharmaceutical industry. Thanks to a business history of more than 50 ...
About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...
About the Company : Founded in 1997, Lee Pharma Limited has transformed from a small venture into a global leader in the pharmaceutical industry. Our journey began with a commitment to providing affor...
About the Company : Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing p...
About the Company : Micro Labs Limited is a diversified healthcare company with cutting-edge R&D, advanced manufacturing facilities, and a strong distribution network. It ranks among India's top pharm...
About the Company : Raghava Life Sciences Pvt. Ltd. (RLS), established in the year 2018, is an integrated small molecules chemistry Contract research, Development and Manufacturing Organization (CDMO)...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
81
PharmaCompass offers a list of Deucravacitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Deucravacitinib manufacturer or Deucravacitinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Deucravacitinib manufacturer or Deucravacitinib supplier.
PharmaCompass also assists you with knowing the Deucravacitinib API Price utilized in the formulation of products. Deucravacitinib API Price is not always fixed or binding as the Deucravacitinib Price is obtained through a variety of data sources. The Deucravacitinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Deucravacitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Deucravacitinib, including repackagers and relabelers. The FDA regulates Deucravacitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Deucravacitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Deucravacitinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Deucravacitinib supplier is an individual or a company that provides Deucravacitinib active pharmaceutical ingredient (API) or Deucravacitinib finished formulations upon request. The Deucravacitinib suppliers may include Deucravacitinib API manufacturers, exporters, distributors and traders.
click here to find a list of Deucravacitinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Deucravacitinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Deucravacitinib active pharmaceutical ingredient (API) in detail. Different forms of Deucravacitinib DMFs exist exist since differing nations have different regulations, such as Deucravacitinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Deucravacitinib DMF submitted to regulatory agencies in the US is known as a USDMF. Deucravacitinib USDMF includes data on Deucravacitinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Deucravacitinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Deucravacitinib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Deucravacitinib Drug Master File in Korea (Deucravacitinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Deucravacitinib. The MFDS reviews the Deucravacitinib KDMF as part of the drug registration process and uses the information provided in the Deucravacitinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Deucravacitinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Deucravacitinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Deucravacitinib suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Deucravacitinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Deucravacitinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Deucravacitinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Deucravacitinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Deucravacitinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Deucravacitinib suppliers with NDC on PharmaCompass.
Deucravacitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Deucravacitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Deucravacitinib GMP manufacturer or Deucravacitinib GMP API supplier for your needs.
A Deucravacitinib CoA (Certificate of Analysis) is a formal document that attests to Deucravacitinib's compliance with Deucravacitinib specifications and serves as a tool for batch-level quality control.
Deucravacitinib CoA mostly includes findings from lab analyses of a specific batch. For each Deucravacitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Deucravacitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Deucravacitinib EP), Deucravacitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Deucravacitinib USP).